Annual Secretarial Compliance Report for the year ended 31st March, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fredun Pharmaceuticals Ltd has filed its Annual Secretarial Compliance Report for FY 2025-26, reviewed by Practicing Company Secretary Kala Agarwal. The company reported general compliance with SEBI regulations including LODR, ICDR, and PIT regulations. One temporary non-compliance was noted: the Board had fewer than 6 directors during two periods (June-July 2025 and September-November 2025), falling short of Regulation 17(1)(c) requirements. This occurred due to the sudden demise of Executive Director Mr. Nariman Medhora and completion of tenure of two Independent Directors. The Board has since been reconstituted and is now compliant. No deviations were found in secretarial standards, related party transactions, website disclosures, or preservation of documents.
The temporary board composition issue has been rectified, and no further action or penalties were reported. Shareholders can view this as a routine compliance report with no material concerns, though the board transition events may warrant monitoring for any impact on governance stability.